Navitor is now approved as a minimally invasive alternative to surgery for patients in Europe with symptomatic, severe aortic stenosis (a common and life-threatening heart valve disease) who are at low or intermediate surgical risk CE Mark is based on safety and effectiveness data from the VANTAGE trial presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in JACC: Cardiovascular Interventions Updated guidelines announced for the management of valvular

- Company must regain compliance with the Nasdaq Bid Price Rule on or before the October 17, 2025 deadline - SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, announced that it received a decision letter (the “Letter”) from the Nasdaq Hearings Panel (the “Panel”) on August 27, 2025, granting

HONG KONG, Aug. 29, 2025 /PRNewswire/ -- On the morning of 29 August, Guo Guangchang, Chairman of Fosun International, stated at the Company's 2025 interim results presentation that Fosun will continue to increase investment in biopharmaceuticals and focus on deepening and thoroughly developing its advantageous industries to secure a commanding global position. The interim results presentation was held in Shanghai this morning, with attendees including Chairman Guo Guangchang, Co-Chairman Wang Q

Patient Square Capital, the large healthcare investment firm led by Jim Momtazee, has raised at least $3.1 billion so far for a second fund, according to a securities filing , though the final amount could be significantly larger. The global investment firm has been fundraising for Patient Square Equity Partners II for at least 15 months, according to the Friday SEC filing. Momtazee previously spent about two decades at KKR, where he built out the massive asset manager’s healthcare strategy. He’

Plus news about Foresee Pharmaceuticals: ☑ Zydus Therapeutics’ PBC data: The drug saroglitazar met the primary endpoint in a Phase 2b/3 trial for a rare autoimmune disease that affects the bile ducts, the company announced Friday. The trial enrolled patients who had failed on ursodeoxycholic acid, the current standard of care in primary biliary cholangitis (PBC). There was a statistically significant difference in the percentage of patients who received saroglitazar and achieved a biochemical re

Johnson & Johnson is expecting its newly-approved Imaavy to be a multibillion-dollar blockbuster across several conditions. But a stumble in a major disease category could hurt those plans. Imaavy (nipocalimab) failed a Phase 2a rheumatoid arthritis study, the company reported Thursday afternoon . Researchers were testing the drug as part of a regimen with an anti-TNF alpha therapy, and the trial showed that the combination did not have a “significant added benefit” compared with the control gro

DALLAS, Aug. 29, 2025 /PRNewswire/ -- At Taiwan Expo USA 2025 in Dallas, the Smart Healthcare Pavilion, organized by the International Trade Administration (TITA) and the Taiwan External Trade Development Council (TAITRA), highlighted Taiwan's accelerating role in global digital health innovation. The pavilion brought together leading organizations introducing new approaches across telemedicine, artificial intelligence (AI), precision medicine, and next-generation medical services, as reported b

As the markets have tightened, biopharma companies have gotten creative with their dealmaking structures in recent years. One route — the single-asset deal — has become popular in 2025. Eli Lilly , Sanofi , GSK and AbbVie have all taken the approach this year, with AbbVie’s acquisition of a psychedelic compound from its existing partner Gilgamesh Pharmaceuticals as the latest example. Some of the single-asset deals include a “spin-co” model, with Pfizer’s Biohaven deal in 2022 setting the bluepr

BeOne Medicines said its candidate for a rare but aggressive form of B cell lymphoma has passed an early-stage test. Its BCL2 inhibitor, known as sonrotoclax, met the primary endpoint of overall response rate in a single-arm Phase 1/2 study of 125 patients with relapsed or refractory mantle cell lymphoma (MCL). The participants received sonrotoclax following treatment with anti-CD20 therapy and a BTK inhibitor, according to a Friday release . Sonrotoclax also demonstrated “promising results” in

STOCKHOLM, Aug. 29, 2025 /PRNewswire/ -- As per 29 August 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares, of which 356,000,049 are common shares and 1,412,788 are C-shares. The total number of votes is 356,141,327,8. The increase in the number of shares and votes results from issues of 1,412,788 class C shares. The class C shares have been issued for the purpose of ensuring fulfilment of commitments under the long-term incentive progr